Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck’s delay of filing an NDA for its osteoporosis drug odanacatib surprised analysts, but Merck remained mum on its reasoning in a year-end earnings call on Feb. 1.

You may also be interested in...

Merck Moves Forward With Odanacatib Filing; FDA Accepts MK-3475 Filing

At a May 6 investor day, Merck’s R&D head Roger Perlmutter revealed the safety issues that have been delaying the company’s late-stage osteoporosis drug and tried to renew confidence in the treatment.

Emerging Markets Earnings Roundup: Merck And Novo Nordisk (Part 5)

In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts